Recent 8-K filings for WVE

• May 18, 2026, 4:51 PM ET other material materiality 0.80 positive item 7.01item 8.01item 9.01

  Wave Life Sciences WVE-006 phase 1b/2a data shows MZ-like phenotype with monthly dosing, FDA feedback expected mid-2026

  WVE-006 achieved 64.4% wild-type M-AAT (matching protective MZ phenotype) and 70.5% reduction in toxic Z-AAT in 200 mg biweekly cohort.

• April 28, 2026, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 7.01item 9.01 ◈ Earnings Releases

  Wave Q1 revenue $38.2M; net loss narrows to $26.1M; WVE-007 Phase 2a begins Q2 2026

  Revenue $38.2M (up from $9.2M); net loss $26.1M (vs $46.9M).

• April 21, 2026, 7:59 PM ET other material materiality 0.50 neutral item 8.01item 9.01

  Wave Life Sciences sets Singapore High Court hearing for redomiciliation on Apr 29

  Application to convene shareholder meeting for scheme of arrangement filed Apr 16, 2026; hearing on Apr 29 at 10:00 am SGT.

• April 15, 2026, 7:59 PM ET other material materiality 0.55 neutral item 1.01item 8.01item 9.01 ◈ Material Agreements

  Wave Life Sciences announces redomiciliation to Delaware, shares to exchange 1:1

  Parent company to change from Singapore to Delaware corporation via scheme of arrangement.

• March 26, 2026, 7:59 PM ET other material materiality 0.90 positive item 7.01item 8.01item 9.01

  Wave Life Sciences Announces Positive Interim Phase 1 Data for WVE-007 in Obesity Trial

  Single 240 mg dose of WVE-007 reduced visceral fat by 14% (placebo-adjusted, p<0.05) at six months.

• February 26, 2026, 6:59 PM ET earnings materiality 0.75 negative item 2.02item 7.01item 9.01

  Wave Life Sciences Q4 net loss $53.2M; cash $602.1M; WVE-007 obesity data update expected Q1 2026

  Net loss $53.2M in Q4 vs income $29.3M YoY; full year loss $204.4M vs $97.0M.

• February 2, 2026, 6:59 PM ET other material materiality 0.75 positive item 8.01item 9.01

  Wave regains full rights to WVE-006; plans FDA accelerated approval engagement mid-2026

  Regained full rights to WVE-006 (RNA editing for AATD) from GSK; no upfront payment mentioned.

• January 12, 2026, 6:59 PM ET other material materiality 0.60 positive item 2.02item 7.01item 9.01

  Wave Life Sciences reports preliminary $602M cash; outlines 2026 pipeline milestones

  Preliminary unaudited cash $602M as of Dec 31, 2025; runway into 3Q 2028.

• December 11, 2025, 6:59 PM ET other material materiality 0.75 neutral item 1.01item 7.01item 8.01item 9.01

  Wave Life Sciences prices upsized $402.5M public offering; extends cash runway to Q3 2028

  Offering: 15,789,475 shares at $19.00 plus 2,631,578 pre-funded warrants at $18.9999.

• December 8, 2025, 6:59 PM ET other material materiality 0.85 positive item 7.01item 8.01item 9.01

  Wave Life Sciences reports positive Phase 1 INLIGHT data: WVE-007 reduces visceral fat 9.4%, preserves lean mass

  Single 240 mg WVE-007 dose: 9.4% visceral fat loss (p=0.02), 4.5% total fat reduction, 3.2% lean mass gain at 3 months.

• November 17, 2025, 6:59 PM ET other materiality 0.05 neutral item 7.01item 9.01

  Wave Life Sciences updates corporate presentation; no material new data disclosed.

  Filed corporate presentation dated November 17, 2025, available on company website.

• November 10, 2025, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Wave Life Sciences Q3 net loss $53.9M; obesity drug WVE-007 shows 85% Activin E reduction

  WVE-007: dose-dependent Activin E reduction up to 85% in INLIGHT; sustained through 6 months at lowest dose; supports once/twice yearly dosing.

• October 30, 2025, 7:59 PM ET other material materiality 0.75 positive item 7.01item 8.01item 9.01

  Wave Life Sciences reports positive WVE-007 target engagement: up to 85% Activin E reduction; WVE-008 candidate selected

  WVE-007 Activin E reductions: 85% (400mg), 75% (240mg), 56% (75mg) at day 29; Cohort 1 durable through 6 months, supporting 1-2x/year dosing.

• October 29, 2025, 7:59 PM ET other material materiality 0.65 positive item 7.01item 8.01item 9.01

  Wave Life Sciences reports positive target engagement data for WVE-007 in obesity; Activin E reductions up to 85%

  WVE-007 achieved Activin E reductions of 85% (400mg), 75% (240mg), 56% (75mg) at one month, all highly significant (p<0.0001).

• September 24, 2025, 7:59 PM ET other material materiality 0.20 neutral item 7.01item 9.01

  Wave Life Sciences releases updated corporate presentation on September 24, 2025

  Presentation posted on company website and furnished as Exhibit 99.1.

• September 3, 2025, 7:59 PM ET other material materiality 0.80 positive item 7.01item 8.01item 9.01

  Wave Life Sciences reports positive WVE-006 data in alpha-1 antitrypsin deficiency study

  200 mg repeat doses achieved 11.9 µM total AAT and 7.2 µM M-AAT, meeting therapeutic levels

• August 11, 2025, 7:59 PM ET other material materiality 0.50 neutral item 5.02item 5.07item 9.01

  Wave Life Sciences shareholders approve 8M share increase to equity plan

  Shareholders approved 8M share increase to 2021 Equity Incentive Plan (105.9M for, 24.6M against).

• August 5, 2025, 7:59 PM ET other material materiality 0.20 neutral item 7.01item 9.01

  Wave Life Sciences updates corporate presentation on August 5, 2025

  Company furnished an updated corporate presentation as Exhibit 99.1 to the 8-K.

• July 30, 2025, 7:59 PM ET earnings materiality 0.70 negative item 2.02item 9.01

  Wave Life Sciences Q2 2025 net loss $50.5M; cash $208.5M; key trial data on track

  Cash $208.5M as of June 30, 2025, down from $302.1M at Dec 31, 2024; runway into 2027.

• May 8, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 7.01item 9.01

  Wave Life Sciences Q1 2025 net loss $46.9M; pipeline progress in obesity, AATD, DMD, HD

  Net loss of $46.9M vs $31.6M prior year; revenue $9.2M (down from $12.5M). Cash $243.1M, runway into 2027.

• March 26, 2025, 7:59 PM ET other material materiality 0.85 positive item 7.01item 8.01item 9.01

  Wave reports positive Phase 2 FORWARD-53 data for WVE-N531 in DMD; plans NDA in 2026

  TTR improved 3.8 seconds vs natural history (p<0.05); fibrosis reduced 28.6% (p<0.01); CK declined 50%.

• March 4, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 7.01item 9.01

  Wave Life Sciences Q4 net income $29.3M; cash $302M; obesity and AATD data expected in 2025

  Q4 2024 revenue $83.7M (up from $29.1M YoY); net income $29.3M vs prior year net loss $16.3M.

• January 13, 2025, 6:59 PM ET other material materiality 0.20 neutral item 7.01item 9.01

  Wave Life Sciences updates corporate presentation, no material details disclosed

  Company furnished an updated corporate presentation on January 13, 2025.

• November 20, 2024, 6:59 PM ET other materiality 0.10 neutral item 7.01item 9.01

  Wave Life Sciences updates corporate presentation; no specific new data disclosed

  Company filed an updated corporate presentation dated November 20, 2024.

• November 12, 2024, 6:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  Wave Life Sciences Q3 net loss $61.8M; first RNA editing in humans for AATD achieved

  Net loss $61.8M vs net income $7.3M in Q3 2023; revenue ($7.7M) vs $49.2M (including one-time events).

• October 30, 2024, 7:59 PM ET other material materiality 0.55 positive item 7.01item 8.01item 9.01

  Wave Life Sciences reveals WVE-007 obesity trial startup in Q1 2025, new RNA editing programs

  WVE-007 (INHBE GalNAc-siRNA) on track for Phase 1 in Q1 2025; preclinical data show monotherapy, add-on to GLP-1s, and maintenance potential.

• October 16, 2024, 7:59 PM ET other material materiality 0.85 positive item 7.01item 8.01item 9.01

  Wave achieves first-ever therapeutic RNA editing in humans in RestorAATion-2 trial of WVE-006

  Single 200 mg dose in first two Pi*ZZ patients produced mean total AAT ~11 µM at day 15, with edited M-AAT >60% of total.

• October 15, 2024, 7:59 PM ET other material materiality 0.75 positive item 7.01item 8.01

  Takeda terminates HTT option; Wave Life Sciences regains full rights to WVE-003 Huntington's program

  Takeda notified Wave it will not exercise option for HTT target, ending collaboration; Takeda previously paid ~$260M to Wave.

• October 1, 2024, 7:59 PM ET other materiality 0.20 neutral item 7.01item 9.01

  Wave Life Sciences posts updated corporate presentation to IR website

  Corporate presentation dated October 1, 2024, posted on investor relations page.

• September 26, 2024, 7:59 PM ET other material materiality 0.85 neutral item 1.01item 7.01item 8.01item 9.01

  Wave Life Sciences prices upsized $200M public offering of ordinary shares and pre-funded warrants

  Offering of 23.1M ordinary shares at $8.00/share and 1.9M pre-funded warrants at $7.9999 each; gross proceeds ~$200M.

• September 24, 2024, 7:59 PM ET other material materiality 0.75 positive item 7.01item 8.01item 9.01

  Wave Life Sciences reports positive interim Phase 2 data for WVE-N531: adjusted dystrophin 9.0% in DMD exon 53

  Mean muscle content-adjusted dystrophin expression 9.0% (range 4.6-13.9%); unadjusted 5.5% (range 3.3-8.3%) in ambulatory boys.

• August 12, 2024, 7:59 PM ET other material materiality 0.50 neutral item 5.02item 5.07item 9.01

  Shareholders approve increase to equity plan shares by 5M at Wave Life Sciences AGM

  Shareholders approved amendment to 2021 Equity Incentive Plan, increasing share authorization by 5,000,000 shares.

• August 8, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 7.01item 9.01

  Wave Life Sciences Q2 net loss $32.9M; positive HD data with up to 46% mHTT reduction; cash $154M into Q4 2025

  Q2 net loss $32.9M vs $21.1M YoY; revenue $19.7M vs $22.1M; cash $154M, sufficient into Q4 2025.

• June 25, 2024, 7:59 PM ET other material materiality 0.85 positive item 7.01item 8.01item 9.01

  Wave Life Sciences reports 46% mHTT lowering in HD trial; allele-selective silencing demonstrated

  SELECT-HD: 30 mg WVE-003 Q8W showed 46% mean mHTT reduction vs placebo at 24 weeks (p=0.0007); 44% at 28 weeks (p=0.0002).

• May 9, 2024, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 7.01item 9.01 ◈ Earnings Releases

  Wave Life Sciences Q1 net loss $31.6M; cash $180.9M; pipeline milestones on track

  Q1 revenue $12.5M (vs $12.9M YoY); net loss $31.6M (vs $27.4M). Cash $180.9M; plus $12M from GSK milestone in April.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.75 · Most common event other_material

19 positive 2 negative 14 neutral

source · WVE on sec.gov